ARS Pharmaceuticals has seen its stock fall more than 65% due to significant commercialization difficulties. The company's new CEO plans to revitalize its FDA-approved no-needle epinephrine product, Neffy, through strict cost controls and focused physician engagement. Despite the high risks, the potential rewards of this turnaround strategy make the stock an intriguing option for investors. The CEO's approach aims to address past challenges and drive a strong recovery moving forward.
Greg Abel, Warren Buffett's successor at Berkshire Hathaway, invested about $17 billion in Alphabet during Q2 2026, making it a core holding. This move aligns with Alphabet's strong fundamentals, including 24.2% revenue growth and a low valuation. Ab...
Oak Securities has started coverage of Coinsilium Group Limited with a buy rating and a price target of 4.25p, more than double its current 2p share price. Coinsilium, a Gibraltar-based digital asset venture builder holding 182 Bitcoin, is valued aro...
Deutsche Bank downgraded Oxford BioMedica from 'buy' to 'hold' and cut its target price by 26% to 595p due to slower revenue growth and delays in its programmes. The bank noted operational issues at the company's Durham site and weaker visibility ahe...
Hosts of Earn Your Leisure highlight NVIDIA's $500 billion AI investment partnership with major firms as a transformative digital infrastructure project. This large-scale funding, likened to a public works program, signals strong institutional confid...
UATP has partnered with dLocal, a leading cross-border payment platform, to enhance its UATP One merchant services by adding local payment processing capabilities across Latin America, Africa, the Middle East, and Asia. This partnership allows airlin...
